Workflow
昆药集团(600422):业绩略有承压,渠道重构加速
600422KPC(600422) 浙商证券·2025-04-29 12:24

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company reported a slight decline in performance, with Q1 2025 revenue at 1.608 billion yuan, down 16.53% year-on-year, and net profit attributable to shareholders at 90 million yuan, down 31.06% year-on-year. This decline is attributed to the company's ongoing channel restructuring and transformation efforts, which are currently facing transitional pressures [6] - The company is expected to achieve sequential revenue and profit growth throughout 2025, with a projected double-digit increase in net profit for the year. This growth is anticipated as the company enhances channel efficiency and brand value through its restructuring efforts [6] - The company is actively promoting its brand renewal and has launched various marketing initiatives to enhance product visibility and reach, particularly targeting younger demographics through platforms like Xiaohongshu and Bilibili [6] Financial Summary - Revenue projections for 2024 to 2027 are as follows: 8.401 billion yuan in 2024, 8.826 billion yuan in 2025 (up 5.06%), 9.770 billion yuan in 2026 (up 10.69%), and 10.753 billion yuan in 2027 (up 10.06%) [2][7] - Net profit attributable to shareholders is projected to grow from 648 million yuan in 2024 to 718 million yuan in 2025 (up 10.83%), 826 million yuan in 2026 (up 15.06%), and 962 million yuan in 2027 (up 16.39%) [2][7] - Earnings per share (EPS) is expected to increase from 0.86 yuan in 2024 to 0.95 yuan in 2025, 1.09 yuan in 2026, and 1.27 yuan in 2027 [2][7] - The price-to-earnings (P/E) ratio is projected to decrease from 17.94 in 2024 to 12.09 in 2027, indicating improving valuation metrics over the forecast period [2][7]